# SAE Capabilities Mapped to 6 Pillars of Cancer Intelligence

**Date:** January 28, 2025  
**Status:** ‚úÖ **ACTIVE** - SAE capabilities mapped to 6 Pillars  
**Location:** `.cursor/MOAT/SAE_INTELLIGENCE/05_SAE_CAPABILITIES.md`  
**See Also:** [00_MISSION.mdc](00_MISSION.mdc) for mission overview, [03_GENERALS_BATTLE_MAP.mdc](03_GENERALS_BATTLE_MAP.mdc) for 6 Pillars framework

---

## üîó SAE CAPABILITIES ‚Üí 6 PILLARS MAPPING

### **PILLAR 1: TUMOR BURDEN** ‚Üí SAE Contribution

**What SAE Provides:**
- ‚úÖ **CA-125 Intelligence Integration**
  - SAE resistance detection uses CA-125 trends (2-of-3 triggers)
  - CA-125 inadequate response (<50% drop by Cycle 3) ‚Üí resistance trigger
  - Baseline CA-125 tracked for resistance monitoring

**What's Missing:**
- ‚ùå Imaging-based tumor burden (CT/PET RECIST) - not integrated
- ‚ùå ctDNA tumor fraction tracking - partially built
- ‚ùå CTC count tracking - not built

**Connection Point:**
```
CA-125 Test ‚Üí SAE Resistance Detection ‚Üí Trigger System ‚Üí Actions
  ‚Üì
Pattern: Rising after nadir ‚Üí Resistance signal
  ‚Üì
Action: Order ctDNA, search trials, escalate to tumor board
```

---

### **PILLAR 2: GENOMIC EVOLUTION** ‚Üí SAE Contribution ‚≠ê **PRIMARY PILLAR**

**What SAE Provides:**
1. ‚úÖ **DNA Repair Capacity** (Manager's C1 Formula)
   - Computes DNA repair capacity from mutations
   - Formula: `0.6√óDDR_pathway + 0.2√óHRR_essentiality + 0.2√óexon_disruption`
   - Example: BRCA1 biallelic ‚Üí DNA repair = 0.82 (HIGH)

2. ‚úÖ **Pathway Burden** (7D Mechanism Vector)
   - Computes 7D mechanism vector: [DDR, MAPK, PI3K, VEGF, HER2, IO, Efflux]
   - Source: **Proxy Logic** (Validated Genes)

3. ‚úÖ **Hotspot Detection** (COSMIC Database)
   - Detects KRAS/BRAF/NRAS hotspots
   - Maps to pathways (KRAS ‚Üí MAPK, BRAF ‚Üí MAPK)

4. ‚úÖ **Transcriptomic Risk (L1)**
   - **MFAP4 Biomarker**: High expression -> EMT Phenotype.
   - **AUROC**: 0.763 (Gold Standard).

5. ‚úÖ **Resistance Detection** (2-of-3 Triggers)
   - HRD score drop ‚â•10 points
   - MFAP4 Spike (New)
   - CA-125 inadequate response

**What's Missing:**
- ‚ùå ctDNA VAF tracking over time - partially built
- ‚ùå Clonal evolution detection - not built
- ‚ùå New mutation detection in ctDNA - not built

**Connection Point:**
```
ctDNA Test ‚Üí SAE Feature Service ‚Üí Mechanism Vector ‚Üí Trial Matching
  ‚Üì
Pattern: New TP53 mutation + DDR pathway drop ‚Üí Resistance emerging
  ‚Üì
Action: Re-rank drugs, search salvage trials, update care plan
```

---

### **PILLAR 3: IMMUNE STATUS** ‚Üí SAE Contribution

**What SAE Provides:**
- ‚úÖ **IO Pathway in Mechanism Vector**
  - IO index in 7D mechanism vector: IO = 1.0 if TMB ‚â•20 OR MSI-High
  - IO-eligible patients get checkpoint inhibitors ranked higher
  - Mechanism fit for IO pathway in trial matching

**What's Missing:**
- ‚ùå PD-L1 expression tracking - not built
- ‚ùå TIL (tumor-infiltrating lymphocytes) analysis - not built
- ‚ùå Exhaustion markers (PD-1, TIM-3, LAG-3) - not built

**Connection Point:**
```
TMB Test ‚Üí SAE Mechanism Vector (IO index) ‚Üí Drug Efficacy ‚Üí Trial Matching
  ‚Üì
Pattern: TMB ‚â•10 ‚Üí IO eligible
  ‚Üì
Action: Boost checkpoint inhibitors in drug ranking, match IO trials
```

---

### **PILLAR 4: METABOLIC STATE** ‚Üí SAE Contribution

**What SAE Provides:**
- ‚ùå **Not Built Yet** - This is a new domain

**What Could Be Built:**
- PET-CT SUV max tracking (metabolic activity)
- Glucose/glutamine dependency analysis
- Lactate production tracking
- Metabolic pathway vulnerabilities (IDH mutations, etc.)

**Connection Point (Future):**
```
PET-CT Test ‚Üí Metabolic Analysis ‚Üí SAE Metabolic Features ‚Üí Drug Efficacy
  ‚Üì
Pattern: High SUV despite stable size ‚Üí Metabolically active resistance
  ‚Üì
Action: Consider metabolic inhibitors, escalate therapy
```

---

### **PILLAR 5: MICROENVIRONMENT** ‚Üí SAE Contribution

**What SAE Provides:**
- ‚ùå **Not Built Yet** - This is a new domain

**What Could Be Built:**
- Hypoxia markers (HIF-1Œ±)
- Fibrosis markers (collagen, TGF-Œ≤)
- Treg/MDSC counts (suppressive immune cells)
- Angiogenesis markers (VEGF) - partially in mechanism vector

**Connection Point (Future):**
```
Microenvironment Test ‚Üí SAE Microenvironment Features ‚Üí Drug Efficacy
  ‚Üì
Pattern: High VEGF + hypoxia ‚Üí Aggressive microenvironment
  ‚Üì
Action: Consider bevacizumab, anti-angiogenic trials
```

---

### **PILLAR 6: TOXICITY/TOLERANCE** ‚Üí SAE Contribution

**What SAE Provides:**
- ‚ö†Ô∏è **Indirect Contribution**
  - SAE doesn't directly compute toxicity, but:
  - Resistance detection can trigger dose adjustments
  - Pathway burden changes can indicate tolerance issues

**What's Missing:**
- ‚ùå Comprehensive toxicity tracking - partially built
- ‚ùå Dose adjustment recommendations - not built
- ‚ùå Supportive care recommendations - not built

**Connection Point:**
```
PGx Test ‚Üí Toxicity Risk ‚Üí SAE Resistance Detection ‚Üí Care Plan
  ‚Üì
Pattern: DPYD variant detected ‚Üí 5-FU toxicity risk
  ‚Üì
Action: Avoid 5-FU, suggest alternative, adjust dose
```

---

## üìä SAE FEATURES BY PILLAR

| SAE Feature | Pillar(s) | Status | Impact |
|-------------|-----------|--------|--------|
| **DNA Repair Capacity** | Pillar 2 (Genomic Evolution) | ‚úÖ Operational | HIGH - PARP sensitivity prediction |
| **Pathway Burden (7D)** | Pillar 2 (Genomic Evolution) | ‚úÖ Operational | HIGH - Mechanism-based trial matching |
| **Hotspot Detection** | Pillar 2 (Genomic Evolution) | ‚úÖ Operational | MEDIUM - Targeted therapy hints |
| **Resistance Detection** | Pillar 1 (Tumor Burden) + Pillar 2 (Genomic Evolution) | ‚úÖ Operational | HIGH - Early resistance detection |
| **IO Pathway Index** | Pillar 3 (Immune Status) | ‚úÖ Operational | MEDIUM - IO eligibility in mechanism vector |
| **VEGF Pathway** | Pillar 5 (Microenvironment) | ‚ö†Ô∏è Partial | LOW - In mechanism vector, not fully utilized |

---

## üéØ STRATEGIC VALUE

### **SAE as Intelligence Source**

**For Pillar 2 (Genomic Evolution):**
- ‚úÖ **Primary Intelligence Source** - SAE is the core capability
- ‚úÖ **DNA Repair Capacity** - Predicts PARP sensitivity
- ‚úÖ **Pathway Burden** - Guides mechanism-based matching
- ‚úÖ **Resistance Detection** - Early warning system

**For Other Pillars:**
- ‚ö†Ô∏è **Supporting Role** - SAE contributes but not primary
- ‚ö†Ô∏è **Integration Points** - SAE features used by other systems
- ‚ö†Ô∏è **Future Expansion** - Can add metabolic/microenvironment features

---

## üîó Related Files

**SAE System Debrief:**
- [01_SAE_SYSTEM_DEBRIEF.mdc](01_SAE_SYSTEM_DEBRIEF.mdc) - Complete debrief

**Strategic Framework:**
- [03_GENERALS_BATTLE_MAP.mdc](03_GENERALS_BATTLE_MAP.mdc) - 6 Pillars framework

**Intelligence Flow:**
- [04_INTELLIGENCE_FLOW.md](04_INTELLIGENCE_FLOW.md) - Test ‚Üí Signals ‚Üí Patterns ‚Üí Actions

---

*Document Owner: Zo*  
*Last Updated: January 28, 2025*  
*Status: ‚úÖ ACTIVE - SAE capabilities mapped to 6 Pillars*


